X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Dr. Reddys with Cipla - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. REDDYS LAB vs CIPLA - Comparison Results

DR. REDDYS LAB     Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. REDDYS LAB CIPLA DR. REDDYS LAB/
CIPLA
 
P/E (TTM) x 22.5 28.0 80.3% View Chart
P/BV x 3.1 3.0 103.4% View Chart
Dividend Yield % 0.8 0.6 134.8%  

Financials

 DR. REDDYS LAB   CIPLA
EQUITY SHARE DATA
    DR. REDDYS LAB
Mar-19
CIPLA
Mar-18
DR. REDDYS LAB/
CIPLA
5-Yr Chart
Click to enlarge
High Rs2,875663 433.6%   
Low Rs1,888479 394.2%   
Sales per share (Unadj.) Rs930.2189.0 492.1%  
Earnings per share (Unadj.) Rs117.417.6 667.4%  
Cash flow per share (Unadj.) Rs185.834.0 545.9%  
Dividends per share (Unadj.) Rs20.003.00 666.7%  
Dividend yield (eoy) %0.80.5 159.8%  
Book value per share (Unadj.) Rs844.4176.7 477.8%  
Shares outstanding (eoy) m166.07805.12 20.6%   
Bonus/Rights/Conversions ESOPESOP-  
Price / Sales ratio x2.63.0 84.8%   
Avg P/E ratio x20.332.5 62.5%  
P/CF ratio (eoy) x12.816.8 76.4%  
Price / Book Value ratio x2.83.2 87.3%  
Dividend payout %17.017.1 99.9%   
Avg Mkt Cap Rs m395,496459,724 86.0%   
No. of employees `00022.023.6 93.0%   
Total wages/salary Rs m33,56226,901 124.8%   
Avg. sales/employee Rs Th7,032.86,446.1 109.1%   
Avg. wages/employee Rs Th1,527.91,139.4 134.1%   
Avg. net profit/employee Rs Th887.7600.0 148.0%   
INCOME DATA
Net Sales Rs m154,482152,193 101.5%  
Other income Rs m3,3753,577 94.4%   
Total revenues Rs m157,857155,769 101.3%   
Gross profit Rs m31,78228,264 112.4%  
Depreciation Rs m11,34813,228 85.8%   
Interest Rs m8891,142 77.8%   
Profit before tax Rs m22,92017,470 131.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m438-28 -1,575.5%   
Extraordinary Inc (Exp) Rs m0-775 0.0%   
Tax Rs m3,8582,501 154.3%   
Profit after tax Rs m19,50014,166 137.7%  
Gross profit margin %20.618.6 110.8%  
Effective tax rate %16.814.3 117.6%   
Net profit margin %12.69.3 135.6%  
BALANCE SHEET DATA
Current assets Rs m111,101108,141 102.7%   
Current liabilities Rs m58,97338,322 153.9%   
Net working cap to sales %33.745.9 73.6%  
Current ratio x1.92.8 66.8%  
Inventory Days Days7997 81.8%  
Debtors Days Days9474 126.6%  
Net fixed assets Rs m101,245109,411 92.5%   
Share capital Rs m8301,610 51.5%   
"Free" reserves Rs m139,406140,682 99.1%   
Net worth Rs m140,236142,292 98.6%   
Long term debt Rs m22,00036,621 60.1%   
Total assets Rs m224,656228,606 98.3%  
Interest coverage x26.816.3 164.4%   
Debt to equity ratio x0.20.3 61.0%  
Sales to assets ratio x0.70.7 103.3%   
Return on assets %9.16.7 135.5%  
Return on equity %13.910.0 139.7%  
Return on capital %14.910.0 150.1%  
Exports to sales %032.8 0.0%   
Imports to sales %00-   
Exports (fob) Rs mNA49,883 0.0%   
Imports (cif) Rs mNANA-   
Fx inflow Rs m88,67351,691 171.5%   
Fx outflow Rs m19,10421,033 90.8%   
Net fx Rs m69,56930,658 226.9%   
CASH FLOW
From Operations Rs m28,70414,628 196.2%  
From Investments Rs m-7,727-8,540 90.5%  
From Financial Activity Rs m-21,326-3,855 553.2%  
Net Cashflow Rs m-3142,431 -12.9%  

Share Holding

Indian Promoters % 25.5 16.0 159.4%  
Foreign collaborators % 0.0 20.8 -  
Indian inst/Mut Fund % 5.4 12.2 44.3%  
FIIs % 35.3 23.7 148.9%  
ADR/GDR % 18.5 1.1 1,681.8%  
Free float % 15.3 26.2 58.4%  
Shareholders   75,885 161,166 47.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. REDDYS LAB With:   ALKEM LABORATORIES  PLETHICO PHARMA  WOCKHARDT  TORRENT PHARMA  FRESENIUS KABI ONCO.  

Compare DR. REDDYS LAB With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Flat; Energy and Automobiles Stocks Drag(09:30 am)

Asian share markets are higher today as Japanese and Hong Kong shares show gains. The Nikkei 225 is up 0.9% while the Hang Seng is up 0.2%.

Related Views on News

CIPLA Announces Quarterly Results (4QFY19); Net Profit Up 144.0% (Quarterly Result Update)

May 24, 2019 | Updated on May 24, 2019

For the quarter ended March 2019, CIPLA has posted a net profit of Rs 4 bn (up 144.0% YoY). Sales on the other hand came in at Rs 44 bn (up 19.1% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA Announces Quarterly Results (3QFY19); Net Profit Up 17.5% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, CIPLA has posted a net profit of Rs 3 bn (up 17.5% YoY). Sales on the other hand came in at Rs 40 bn (up 2.4% YoY). Read on for a complete analysis of CIPLA's quarterly results.

DR. REDDYS LAB Announces Quarterly Results (3QFY19); Net Profit Up 67.0% (Quarterly Result Update)

Feb 4, 2019 | Updated on Feb 4, 2019

For the quarter ended December 2018, DR. REDDYS LAB has posted a net profit of Rs 5 bn (up 67.0% YoY). Sales on the other hand came in at Rs 39 bn (up 0.8% YoY). Read on for a complete analysis of DR. REDDYS LAB's quarterly results.

CIPLA Announces Quarterly Results (2QFY19); Net Profit Down 15.8% (Quarterly Result Update)

Nov 12, 2018 | Updated on Nov 12, 2018

For the quarter ended September 2018, CIPLA has posted a net profit of Rs 4 bn (down 15.8% YoY). Sales on the other hand came in at Rs 40 bn (down 1.7% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA Announces Quarterly Results (1QFY19); Net Profit Up 4.7% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, CIPLA has posted a net profit of Rs 4 bn (up 4.7% YoY). Sales on the other hand came in at Rs 39 bn (up 11.7% YoY). Read on for a complete analysis of CIPLA's quarterly results.

More Views on News

Most Popular

2 Stocks from Super Investor Sanjay Bakshi's Portfolio You Can Bet On...(The 5 Minute Wrapup)

Jul 12, 2019

Despite the current fear prevailing in the markets, both these stocks have the potential to deliver in 4-5 years.

The Electric Vehicle Disruption is Great News for this Smallcap Stock(Profit Hunter)

Jul 15, 2019

While big auto makers are finding the transition difficult and crying foul, this small cap company is already leading and benefitting from the electric vehicle disruption in the auto sector.

Here's What to Do with Falling Small Cap Stocks(Profit Hunter)

Jul 10, 2019

There are some great buying opportunities in the market right now - and the small cap space is your best bet.

7 Stocks to Profit From an Irreversible Trend(The 5 Minute Wrapup)

Jul 18, 2019

Credit growth is likely to accelerate in India in the next decade. Here's how you can benefit from this megatrend.

Budget an Icing on the Cake for This Smart Money Backed Affordable Housing Stock(The 5 Minute Wrapup)

Jul 10, 2019

Affordable housing is one of the most straightforward growth stories in India. This will help the real estate sector to come out of the slump.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


Jul 23, 2019 10:19 AM

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB 5-YR ANALYSIS

COMPARE DR. REDDYS LAB WITH

MARKET STATS